Enterococcus cecorum glycans in vaccine and therapeutic applications
By engineering bacteria to express conserved Enterococcus cecorum glycans, a vaccine and antibody approach effectively targets and prevents Enterococcal spondylitis and Vertebral Osteoarthritis in chickens, addressing antibiotic resistance and vaccine failures.
Patent Information
- Application Number
- PCT/CA2026/050655
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-05
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
The rise of antibiotic resistance in pathogenic Enterococcus cecorum strains has rendered traditional antibiotic treatments ineffective, and existing vaccines fail to provide protection against Enterococcal spondylitis and Vertebral Osteoarthritis in chickens, necessitating a new approach to target conserved glycans for immunogenic potential.
Engineering a non-pathogenic bacterium, such as Salmonella enterica serovar Typhimurium or Escherichia coli, to express capsular polysaccharide (CPS) and rhamnose-rich polysaccharide (RPS) from Enterococcus cecorum, which are used to generate specific antibodies and develop a vaccine composition for oral, in ovo, or parenteral administration, along with antibodies that bind specifically to these glycans for diagnosis and treatment.
The vaccine composition induces protective immune responses in chickens, reducing colonization and symptoms of Enterococcal spondylitis and Vertebral Osteoarthritis, while providing a diagnostic tool for pathogen identification.
Smart Images

Figure CA2026050655_12112026_PF_FP_ABST
Abstract
Description
ENTEROCOCCUS CECORUM GLYCANS IN VACCINE AND THERAPEUTIC APPLICATIONSCROSS-REFERENCE TO RELATED APPLICATION(S)
[0001] The present application claims priority from, and the benefit of, United States Provisional Patent Application No. 63 / 800,286 filed on May 5, 2025, the entire contents of which are incorporated herein by reference.SEQUENCE LISTING
[0002] The present application is being filed along with a Sequence Listing in ST.26 XML format. The Sequence Listing is provided as a file titled “SEQ ID Listings Vaxalta.xml” created May 4, 2026, and is 13.4 kilobytes in size. The Sequence Listing information in the ST.26 XML format is incorporated herein by reference in its entirety.FIELD
[0003] This application pertains to surface glycans from Enterococcus cecorum, expression of glycans in a heterologous system, and methods for using the glycans to prevent, treat, and diagnose disease caused by pathogenic E. cecorum.BACKGROUND
[0004] Pathogenic strains of Enterococcus cecorum are a concern based on their ability to cause the skeletal diseases Enterococcal spondylitis (ES) and Vertebral Osteoarthritis (VOA), colloquially known as “kinky back” (Jung et al., 2018), which are a significant cause of morbidity and mortality in chickens, especially in broilers for meat production and their breeding hens. Previously, these infections were managed by prophylactic antibiotic treatment that was used routinely to reduce bacterial colonization of chickens in food production settings. However, this prolonged use of antimicrobials has led to a concerning rise in the development of antibiotic resistance, thus their use in livestock feed is no longer permitted in many countries. Of particular note, pathogenic E. cecorum has been identified among the most relevant antimicrobial resistant (AMR) bacteria in the EU and is known for spreading determinants of antibiotic resistance. Thus, there is a need to develop other means to prevent pathogenic E. cecorum infections.1WSLEGAL\088094\00003\44113916v7
[0005] Vaccination of broiler breeders with mixtures of inactivated pathogenic strains of / :. cecorum, resulted in the production of E. cecorum specific antibodies in the hens; however, no protection of the progeny was observed (Borst et al., 2019). Previous studies have shown that the use of hyperimmune E. cecorum serum administered subcutaneously can provide passive protection in broilers; however, this specific treatment did not entirely prevent disease and is not practical for production level administration (Rosenbaum et al., 2025).
[0006] E. cecorum is generally commensal in chickens and only specific pathogenic strains cause disease. Such pathogenic strains preferentially and highly effectively colonize the chicken gastrointestinal tract in the first week of life and then other tissues, whereas commensal strains tend to colonize after the third week of life and rarely move into other parts of the body (Borst et al., 2016). Traditionally, commensal and pathogenic strains were largely defined based on their isolation source rather than on specific phenotypic features since there was limited information on characteristics such as virulence factors, antimicrobial resistance or serotypes. However, recent efforts have been made using comparative genomics to identify distinct features of genomes from pathogenic strains compared to their commensal counterparts and suggest that most pathogenic strains around the world are closely-related (Borst et al., 2015; Jackson et al., 2015; Laurentie et al., 2023; Rhoads et al., 2024). These efforts have identified genetic loci predicted to encode a capsular polysaccharide (CPS) and a rhamnose-glucose polysaccharide (RGP) that are highly conserved amongst pathogenic isolates (Borst et al., 2015; Laurentie et al., 2023; Rhoads et al., 2024), although very few exceptions exist (Rhoads et al., 2024). It has also been suggested that the presence of these surface glycans, particularly CPS, may have contributed to the failure of the past vaccination attempts since maternal antibodies were unable to kill pathogenic E. cecorum in vitro potentially due to the capsule obscuring antigens recognized by phagocytes (Borst et al., 2019). Thus, it may be more effective to develop a vaccine that targets the conserved glycans directly.
[0007] Vaccines based on bacterial glycans show strong immunogenic potential and several techniques have been optimized for their use in vaccine development and commercialization (Kay et al., 2019). However, these often require the complete identification of the biosynthetic enzymes from the pathway and gene transfer into a non-pathogenic carrier host for production of recombinant glycoproteins or use as a whole cell vaccine strain.2WSLEGAL\088094\00003\44113916v7SUMMARY
[0008] The Summary is provided to introduce a selection of concepts that are further described below in the Detailed Description. This Summary is not intended to identify key or essential features of the claimed subject matter, nor is it intended to be used as an aid in limiting the scope of the claimed subject matter
[0009] In one aspect, the present invention relates to the structure and heterologous expression of the conserved capsular polysaccharide (CPS) and the rhamnose-rich polysaccharide (rhamnopolysaccharide or RPS) produced by pathogenic E. cecorum. The present invention also relates to their use for producing CPS and RPS-specific antibodies and / or in providing protection from disease, particularly Enterococcal spondylitis (ES) and Vertebral Osteoarthritis (VOA), induced by pathogenic E. cecorum, as well as use in diagnostics and identification of the pathogen and other microbes with similar glycans.
[0010] Thus, in one aspect, disclosed is an attenuated or non-pathogenic bacterium which has been engineered to heterologously express an E. cecorum surface glycan, such as a capsular polysaccharide (CPS), a rhamnopolysaccharide (RPS), a lipoteichoic acid (LT A) or a teichoic acid-containing glycan.
[0011] In some embodiments, the bacterium is Gram-negative, such as a Salmonella enterica serovar Typhimurium or an Escherichia coli. In some examples, the composition comprises live, engineered Salmonella or E. coli, or live, attenuated, engineered Salmonella or E. coli, or other suitable bacterial carriers. Alternatively, the composition comprises inactivated or killed engineered E. coli or S. Typhimurium.
[0012] In some embodiments, the S. Typhimurium is non-pathogenic and lacks all native glycosyltransferases.
[0013] In some embodiments, the CPS comprises a repeating oligosaccharide having a galacturonic acid (GalA) residue which is acetylated in an approximate 1:1 ratio on either the second or third carbon. In some embodiments, the ratio is between about 0.7: 1.0 to about 1.0:0.7, preferably between about 0.8: 1.0 to about 1.0:0.8, or more preferably between about 0.9: 1.0 to about 1.0:0.9.3WSLEGAL\088094\00003\44113916v7
[0014] In some embodiments, the RPS comprises a repeating rhamnose backbone lacking glucose side chain modifications that are observed in rhamnose-glucose polysaccharide (RGP) variants of RPS, such as the E. cecorum surface glycan RGP.
[0015] In at least one broad aspect, there is provided a vaccine composition comprising a bacteria described herein, engineered to heterologously express at least one E. cecorum surface glycan on their cell surface, and one or more of a physiologically acceptable diluent, excipient, adjuvant or carrier, such as a suitable buffered diluent, such as phosphate buffered saline.
[0016] In some examples, the vaccine composition can be formulated for oral administration, in ovo administration or parenteral administration (e.g., by injection or infusion). In some examples, the vaccine composition is formulated to be sprayed or for addition to livestock feed, feed additive or water. In some examples, the vaccine composition can be formulated for administration to poultry, for example, chickens.
[0017] In another aspect, disclosed is an antibody that binds specifically to an E. cecorum surface glycan described herein, for example, an antibody isolated from an animal which has been vaccinated with a E. cecorum surface glycan.
[0018] In another aspect, disclosed is a method of treating or preventing a disease caused by microbes bearing E. cecorum surface glycan or related glycans by administrating a vaccine as described herein, or an antibody described herein, or sera which comprises such an antibody. In some embodiments, the disease may be caused by E. cecorum or Streptococcus mutans, or any bacteria with a surface glycan comprising a RPS backbone.
[0019] In yet another aspect, disclosed is a method of diagnosing an infection caused by E. cecorum by using antibodies described herein in an assay to detect E. cecorum in a sample.
[0020] In yet another aspect, disclosed herein is a method and assay for evaluating E. cecorum binding and killing by opsonophagocytosis, using antibodies described herein.4WSLEGAL\088094\00003\44113916v7BRIEF DESCRIPTION OF THE DRAWINGS
[0021] The present application includes the following figures and tables. The figures and tables are intended to illustrate or demonstrate certain embodiments and / or features of the compositions and methods, and to supplement any description(s) of the compositions and methods. The figures and tables do not limit the scope of the compositions and methods, unless the written description expressly indicates that such is the case.
[0022] Figure 1 is a schematic of the key CPS and RGP biosynthetic loci found in pathogenic E. cecorum.
[0023] Figure 2 shows polyacrylamide gels and a western immunoblot demonstrating that surface carbohydrates from E. cecorum are immunogenic in chickens. Particularly, the figure shows (a) Coomassie stain of whole cell lysates from indicated E. cecorum or S. mutans strains, with proteins remaining; (b) silver stain of carbohydrates remaining following proteinase K treatment, and (c) immunoblot with antisera from a chicken vaccinated with inactivated EcRl cells in adjuvant.
[0024] Figure 3 shows polyacrylamide gels and western immunoblots demonstrating that Salmonella enterica serovar Typhimurium LT2 (5. Typhimurium) can be used for the heterologous expression of E. cecorum glycans, and generates chicken antisera that is cross reactive to multiple pathogenic E. cecorum isolates. Particularly, this figure confirms heterologous synthesis of Ec-CPS by silver stain (a) of protein-free cell extracts where distinct “laddering” of synthesized glycan can be observed in ST with the added genes for synthesis of Ec-CPS; (b) immunoblot of protein-free cell extracts with sera pooled from chickens vaccinated with inactivated ST Ec-CPS showing cross-reactivity to both the heterologous strain and multiple isolates of E. cecorum. The molecular weights (MW) for the standard ladder in kilodaltons (kDa) are noted on the left of the gel or blot images; and (c-d) equivalent data to A-B for ST Ec-RPS.
[0025] Figure 4 shows the Nuclear Magnetic Resonance (NMR) spectra for the characterization of the surface polysaccharides CPS and RGP from pathogenic E. cecorum and the heterologous production of their backbone structures in S. Typhimurium. Particularly, this figure shows: (a)JH-13C HSQC spectra of native (blue) and O-deacylated (red) capsular polysaccharide (CPS).1H trace is for native glycan. (b) spectra of native Ec-CPS (blue) and of ST Ec-CPS (magenta). Some signals are shifted due to different pH. Different intensity is due to differences in acetylation degree (C box), but 5WSLEGAL\088094\00003\44113916v7the core structures (c) are identical; (d)JH-13C HSQC spectrum of the purified rhamnose-glucose polysaccharide (RGP); and (e) HSQC+HMBC spectra of ST Ec-RPS. The rhamnan backbones (F) are identical, but ST Ec-RPS is lacking P-Glc (F box), to promote broader protection.
[0026] Figure 5 shows NMR spectra from an additional polysaccharide, lipoteichoic acid (LTA), that were also identified and may be evaluated as an additional vaccine target. Particularly, this figure shows structural characterization of Enterococcus cecorum lipotechoic acid (LTA), containing major signals of polyglycerophosphate and small signals of two monosaccharides, a-Glc and a-Gal. CorrespondingJH-13C HSQC spectrum (a) and overlap spectra (b) of theJH-13C HSQC (blue-green), HMBC (black), and HSQC-TOCSY (magenta) are shown, and (c) schematic of the LTA structure.
[0027] Figure 6 shows a timeline for the generation of chicken antisera against A. cecorum (Ec)-CPS and Ec-RPS expressed in S. Typhimurium and images of western immunoblots demonstrating cross-reactivity to A. cecorum. Particularly, this figure shows collection of Ec-reactive chicken sera, including (a) timeline for vaccination protocol and sera collection; (b) immunoblots of protein-free whole cell lysates of the indicated bacterial strains probed with sera from chickens vaccinated with inactivated ST Ec-CPS; and (c) equivalent immunoblots probed with sera from chickens vaccinated with inactivated ST Ec-RPS. Molecular weights (MW) of the ladder are indicated in kilodaltons (kDa).
[0028] Figure 7 shows enzyme-linked immunosorbent assays (ELISA) and opsonophagocytosis assays (OP A) demonstrating that sera from chickens vaccinated with the heterologous strain will bind E. cecorum surface glycans of intact cells and induce cell killing. Particularly, this figure shows screening of sera from chickens vaccinated with inactivated ST Ec-CPS or ST Ec-RPS, whereby ELISA was conducted for the strongest reacting sera to CPS (a) or RPS (b) from the immunoblots in Figure 1 and reported as the mean (n=3 technical replicates) absorbance of the indicated wells with the mean from control wells without sera subtracted. Error bars show 1 standard of deviation and asterisks indicate significantly higher signal than the no cell controls (*=p<0.05, **=p<0.005, ***=p<0.0005, ****=p<0.00005) by using a Dunnet’s multiple comparisons test. Figure 7(c) shows opsonophagocytosis assay (OP A) for in vitro killing of E. cecorum using pooled chicken sera from the birds reacting strongest to Ec lysates in immunoblots and ELISA (Sera 1 & 3 for CPS, Sera 5& 8 for RPS). Each dot represents a technical replicate. Asterisks indicate a significant difference from the naive sera by Student’s t-test (**=p<0.005).6WSLEGAL\088094\00003\44113916v7
[0029] Figure 8 shows a timeline for a kinky back model to assess the protective potential of Ec-CPS and Ec-RPS and examples of chickens experiencing symptoms of the disease. Passive protection experiment in a kinky back chicken model system with pooled inactivated whole cell ST Ec-CPS (Figures 6-7, Sera 1&3) or ST Ec-RPS (Figures 6-7, Sera 5&8). (a) Experimental timeline for Ec challenge of 105 broiler chickens allocated into treatment groups containing 35 birds each, (b) Photographs of chickens in the study displaying symptoms of kinky back (splayed out legs and “flattened” body from spinal deformation)
[0030] Figure 9 shows a comparison of bacterial colonization of chicken spleens and free thoracic vertebrae (FTV) with or without treatment with antibodies targeting E. cecorum glycans. E. cecorum colonization of the kinky back model (as described in Figure 8). Day 39 spleen (A) and spinal (B) colonization with individual values shown as dots and means (n=28 to 30, based on number of birds surviving to the Day 39) represented as bars, p-values relative to the untreated group were determined by an unpaired one-tailed T-test.DETAILED DESCRIPTION
[0031] The following description recites various aspects and embodiments of the present compositions and methods. No particular embodiment is intended to define the scope of the compositions and methods. Rather, the embodiments merely provide non-limiting examples of various compositions and methods that are at least included within the scope of the disclosed compositions and methods. The description is to be read from the perspective of one of ordinary skill in the art; therefore, information well known to the skilled artisan is not necessarily included.
[0032] In some embodiments, the present disclosure provides a modified bacterium, exemplified by Salmonella enterica serovar Typhimurium (5. Typhimurium), which expresses a capsular polysaccharide (CPS), a rhamnopolysaccharide (RPS), a lipoteichoic acid, or a techoic acid-containing glycan, from E. cecorum, and compositions comprising the same. Additionally, this disclosure provides for prophylactic and therapeutic methods using the provided compositions.
[0033] The inventors designed, generated, characterized and demonstrated the efficacy of compositions as described herein.7WSLEGAL\088094\00003\44113916v7I. TERMINOLOGY
[0034] The following definitions are provided to assist the reader. Unless otherwise defined, all terms of art, notations, and other scientific or medical terms or terminology used herein are intended to have the meanings commonly understood by those of skill in the chemical and medical arts. In some cases, terms with commonly understood meanings are defined herein for clarity and / or for ready reference, and the inclusion of such definitions herein should not be construed as representing a substantial difference over the definition of the term as generally understood in the art.
[0035] “Glycan” is a polysaccharide compound, consisting of monosaccharides linked glycosidically.
[0036] Immunize refers to rendering a subject protected from an infectious disease, such as by vaccination. In the context of this disclosure, the term also refers to injection of a molecule (i.e. an immunogen) into a subject (e.g., an animal) with the purpose of producing an immune response (e.g., antibodies) against the injected molecule.
[0037] Protective immune response refers to an immune response induced after administration of a vaccine composition to a subject where, upon exposure to the source of the antigenic component of the vaccine (e.g., pathogen or cell expressing the antigen), the clinical symptomatology elicited by the source are diminished.
[0038] Immunogenic and the related terms, when used in the context of the present disclosure, refers to the ability of an antigen (which can be a protein, a polypeptide, oligosaccharide or polysaccharide (i.e. glycan), or a region of a protein or a polypeptide, or a carbohydrate, or an oligosaccharide / polysaccharide (i.e. glycan), for example) to elicit in a subject an immune response to the specific antigen. In the context of the present disclosure, an immune response is the development in a subject of a humoral and / or a cellular immune response to an antigen. A “humoral immune response" refers to an immune response mediated by antibody molecules, including secretory (IgA) or IgG molecules (and chicken IgY molecules), while a “cellular immune response" is one mediated by T-lymphocytes and / or other white blood cells. One important aspect of cellular immunity involves an antigen-specific response by cytolytic T-cells (“CTL”s). CTLs have specificity for peptide antigens that are presented in association with proteins encoded by the major histocompatibility complex (MHC) and expressed on the surfaces of cells. CTLs help induce and promote the destruction of 8WSLEGAL\088094\00003\44113916v7intracellular microbes, or the lysis of cells infected with such microbes. Another aspect of cellular immunity involves an antigen-specific response by helper T-cells. Helper T-cells act to help stimulate the function, and focus the activity of, nonspecific effector cells against cells displaying peptide antigens in association with MHC molecules on their surface. A cellular immune response also refers to the production of cytokines, chemokines and other such molecules produced by activated T-cells and / or other white blood cells, including those derived from CD4+ and CD8+ T-cells. Thus, an immunogenic composition can stimulate CTLs, and / or the production or activation of helper T-cells. The production of chemokines and / or cytokines may also be stimulated. An immunogenic composition may also elicit an antibody-mediated immune response. An immunogenic composition may include one or more of the following effects upon administration to a subject: production of antibodies by B-cells; and / or the activation of suppressor, cytotoxic, or helper T-cells and / or T-cells directed specifically to an antigen present in the immunogenic composition. Various aspects of an immune response elicited by immunogenic compositions can be determined using standard assays, some of which are described in the present disclosure.
[0039] An "E. cecorum surface glycan" is a glycan natively expressed on the surface of E. cecorum, such as a capsular polysaccharide (CPS), a rhamnopolysaccharide (RPS), a lipoteichoic acid (LTA) or a teichoic acid-containing glycan, and immunogenic variations thereof. A capsular polysaccharide is a high-molecular weight glycopolymer which forms a capsule layer on the surface of many bacterial species. An RPS is a polysaccharide based on rhamnose, which can but does not necessarily include a branched sugar or side chain of sugars such as glucose. Rhamnose-glucose polysaccharide ("RGP") is an RPS comprising a rhamnan backbone having glucose side chains.II. FORMULATIONS
[0040] Provided herein are formulations that comprise compositions as described the present disclosure and a pharmaceutically acceptable excipient. In some embodiments, the formulation can further comprise an adjuvant and / or a stabilizing agent, as is known in the art.
[0041] A vaccine composition comprises an engineered bacterium that can be a Gram-positive or Gram-negative bacterium described herein, as a whole cell vaccine. The Gram-negative bacterium can be an S. Typhimurium or an E. coli. The whole cell vaccine can be live, attenuated or inactivated and can be administered in the absence or presence of adjuvant or immunostimulatory compounds.9WSLEGAL\088094\00003\44113916v7The vaccine compositions can further comprise a pharmaceutically acceptable carrier or excipient. In some examples, the vaccine composition may be formulated as a suspension of engineered bacteria in a suitable buffered diluent, including phosphate buffered saline. The vaccine composition may further comprise an adjuvant, stabilizer, preservative, or a combination thereof. The vaccine composition may be formulated for oral administration, in ovo administration (e.g., for avian applications), or parenteral administration, including administration by injection or infusion. In some embodiments, the vaccine composition is formulated as a spray or for addition to livestock feed, a feed additive, or water, including for administration to poultry, such as chickens.
[0042] A "pharmaceutically acceptable carrier" or "excipient" is a material that is not biologically or otherwise undesirable, meaning the material that can be administered to a subject without causing undesirable biological effects or interacting in a deleterious manner with the other components of the pharmaceutical composition in which it is contained. The carrier or excipient is typically selected to minimize degradation of other ingredients of the composition in which the carrier or the excipient is included, and to minimize adverse side effects (such as allergic side effects) in the subject. Examples of aqueous pharmaceutically acceptable carriers include, but are not limited to, sterile water, saline, buffered solutions like Ringer's solution, glycerol solutions, ethanol, dextrose solutions, allantoic fluid, or combinations of the foregoing. The pH of the aqueous carriers is generally about 5 to about 8 or from about 7 to 7.5. A carrier may include a pH-controlling buffer. The preparation of such aqueous carriers ensures sterility, pH, isotonicity, and stability is not affected according to established protocols. Examples of non-aqueous carriers are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Other exemplary carriers include sustained release preparations, such as semipermeable matrices of solid hydrophobic polymers. Other exemplary carriers are matrices in the form of shaped articles, such as, but not limited to, films, liposomes, or microparticles. Certain carriers may be more preferable depending upon, for instance, the composition, the route of administration, and the concentration of composition being administered.
[0043] Formulations according to the embodiments of the present disclosure are generally formulated to be nontoxic or minimally toxic to a / the subject at the dosages and concentrations used for administration. In some embodiments, a formulation of a composition includes an appropriate amount of a pharmaceutically acceptable salt to render the formulation isotonic. In some embodiments, a formulation of a compositions includes components for modifying, maintaining, or preserving, for10WSLEGAL\088094\00003\44113916v7example, the pH, osmolality, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition. A formulation of a composition may include one or more of the following components: amino acids (such as glycine, glutamine, asparagine, arginine or lysine); antimicrobials; antioxidants (such as ascorbic acid, sodium sulfite or sodium hydrogen-sulfite); buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates or other organic acids); bulking agents (such as mannitol or glycine); chelating agents (such as ethylenediaminetetraacetic acid (EDTA)); complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin); fillers; monosaccharides, disaccharides, and other carbohydrates (such as glucose, mannose or dextrins); proteins (such as serum albumin, gelatin or immunoglobulins); coloring, flavoring and diluting agents; emulsifying agents; hydrophilic polymers (such as polyvinylpyrrolidone); low molecular weight polypeptides; salt-forming counterions (such as sodium); preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide); solvents (such as glycerin, propylene glycol or polyethylene glycol); sugar alcohols (such as mannitol or sorbitol); suspending agents; surfactants or wetting agents (such as pluronics, PEG, sorbitan esters, polysorbates such as polysorbate 20, polysorbate 80, triton, tromethamine, lecithin, cholesterol, tyloxapal); stability enhancing agents (such as sucrose or sorbitol); tonicity enhancing agents (such as alkali metal halides, preferably sodium or potassium chloride, mannitol sorbitol); and / or delivery vehicles.
[0044] In some embodiments, the composition is prepared in a dry form (i.e. dehydrated form), such as a lyophilized form. Such a formulation can be referred to as “lyophilized” or a “lyophilizate.” Lyophilization is a process of or freeze-drying, during which a solvent is removed from a liquid formulation. Lyophilization process may include one or more of simultaneous or sequential steps of freezing and drying. Compositions according to the embodiments of the present disclosure can be lyophilized in an aqueous solution comprising a nonvolatile or volatile buffer. Non-limiting examples of suitable nonvolatile buffers are PBS, Tris-HCl, HEPES, or L-Histidine buffer. Non-limiting examples of suitable volatile buffers are ammonium bicarbonate, Ammonia / acetic acid, or N-ethylmorpholine / acetate buffer. A lyophilized composition according to the embodiments of the present disclosure can include appropriate carriers or excipients. Such appropriate excipients may include, but are not limited to, a cryo-preservative, a bulking agent, a surfactant, or their combinations. Exemplary excipients include one or more of a polyol, a disaccharide, or a polysaccharide, such as,11WSLEGAL\088094\00003\44113916v7for example, mannitol, sorbitol, sucrose, trehalose, and / or dextran 40. In some instances, the cryopreservative may be sucrose and / or trehalose. In some instances, the bulking agent may be glycine or mannitol. In one example, the surfactant may be a polysorbate such as, for example, polysorbate-20 and / or polysorbate-80. A lyophilized composition according to the embodiments of the present disclosure can be, for example, in a cake or powder form. Lyophilized compositions may be rehydrated / solubilized / reconstituted in a carrier or excipient (e.g., water or buffer solution) prior to use. Some embodiments of the compositions are reconstituted in a water or buffer solution comprising sucrose.
[0045] Compositions according to embodiments of the present disclosure can be sterile prior to administration to a subject. Sterilization can be accomplished, for example, by filtration through sterile filtration membranes or other methods known in the art. When the composition is lyophilized, sterilization can be conducted either prior to or following lyophilization and reconstitution. The composition can be stored in sterile containers, such as vials or bags, as a solution, suspension, gel, emulsion, solid, or as a dehydrated or lyophilized powder.
[0046] Kits including compositions described in the present disclosure are also included among the embodiments of the present disclosure. For example, a kit may include a composition and a container for its storage, such as a bag or a vial. Such a container may have a sterile access port, for example, a bag or vial having a stopper pierceable by a hypodermic injection needle. In another example, a kit may include a composition in lyophilized or concentrated form. In another example, a kit may include a composition in lyophilized or concentrated form and diluent. In such a kit, a diluent may also be a pharmaceutically acceptable carrier or excipient, as described elsewhere in the present disclosure. Examples of diluents that may be included in such a kit are saline, buffered saline, water, or sucrose. In another example, a kit may include a composition and a device for administering the composition. A device for administering the composition may be a syringe for injection or oral administration (for example, the kit may be a syringe pre-filled with a liquid composition), a microneedle device, such as a microneedle patch, an inhaler, or a nebulizer. For example, a kit may contain multiple vials, syringes or microneedle patches containing a composition. Such administration devices may be single use (i.e., disposable) or reusable.
[0047] In some embodiments, a kit contains a defined amount of a composition capable of eliciting a protective immune response against E. cecorum in an animal, when administered as a single dose.12WSLEGAL\088094\00003\44113916v7In some embodiments, a kit contains multiple doses of a defined amount of a composition capable of eliciting a protective immune response against an E. cecorum in a subject.
[0048] In some embodiments, a kit contains a defined amount of a composition capable of eliciting a protective immune response against E. cecorum infection in an animal, when administered as a single dose (also referred to herein as “an effective amount’). In some embodiments, a kit contains multiple doses of a defined amount of a composition capable of eliciting a protective immune response in a subject.III. METHOD FOR HETEROLOGOUS EXPRESSION OF ENTEROCOCCUS CECORUM SURFACE GLYCANS
[0049] In at least one example, the method of producing and engineering a heterologous E. cecorum gly can-expressing bacterial cell involves: (i) selecting a bacterial host cell, (ii) introducing into the bacterial host cell one or more heterologous E. cecorum glycosynthetic genes, and (iii) culturing the bacterial host cell under conditions in which the one or more heterologous E. cecorum glycosynthetic genes are expressed to produce an E. cecorum surface glycan on or in association with the bacterial host cell.
[0050] In at least one example, the E. cecorum surface glycan comprises an E. cecorum capsular polysaccharide (CPS), and / or an E. cecorum rhamnopolysaccharide (RPS). The E. cecorum glycan can also comprise a cell envelope-associated glycan, such as a teichoic acid-associated glycan (e.g., a lipoteichoic acid (LTA)-associated glycan) or a portion thereof.
[0051] The bacterial host cell may be a Gram-positive or Gram-negative bacterial cell. In at least one example, the bacterial host cell is a Gram-negative bacterium. This includes a Salmonella host cell, such as S. Typhimurium, or it may be Escherichia coli. The bacterial host cell may be attenuated or non-pathogenic.
[0052] The one or more heterologous glycosynthetic genes comprise genes sufficient to assemble at least a portion of an E. cecorum surface glycan, or another cell surface-associated glycan. For example, these may be genes used for assembling CPS, RPS, or a teichoic acid-associated glycan, or portions thereof. For example, the one or more heterologous glycosynthetic genes may comprise glycosyltransferase genes, polymerase genes, flippase genes, modifying enzyme genes,13WSLEGAL\088094\00003\44113916v7acetyltransferase genes, transporter genes, priming glycosyltransferase genes, or combinations thereof (see e.g., FIG.l).
[0053] In some examples, the one or more heterologous E. cecorum glycosynthetic genes are introduced into a host bacterium by delivering one or more nucleic acid constructs comprising the one or more heterologous E. cecorum glycosynthetic genes. For example, the one or more nucleic acid constructs are first propagated in a cloning host, such as E. coll, using a cloning vector, and then isolated and introduced into the host bacterium e.g., via electroporation or any other suitable technique.
[0054] The one or more heterologous E. cecorum glycosynthetic genes may be introduced into the host bacterium as a complete genetic locus, as separate portions of a genetic locus, as genes from two or more loci, or as synthetic or codon-optimized coding sequences.
[0055] In at least one example, the bacterial host cell is initially modified to reduce interference between native glycan biosynthesis, and heterologous glycan biosynthesis. Reduction or elimination of native glycan biosynthesis can decrease background glycan expression and can facilitate detection and production of the heterologous glycan.
[0056] In some example implementations, the bacterial host cell is an attenuated or non-pathogenic S. Typhimurium cell modified to reduce production of native Salmonella surface glycans. For example, the modified S. Typhimurium cell can involve deletions of rfbVUN and wbaP (e.g., to lack all native glycosyltransferase), and the resulting cell comprises one or more plasmids encoding E. cecorum CPS genes and / or E. cecorum RPS genes. Heterologous glycosynthetic genes from an E. cecorum capsular polysaccharide locus or an E. cecorum rhamnose-glucose polysaccharide locus are amplified, cloned into one or more expression vectors, and introduced into the modified S. Typhimurium cell to produce a S. Typhimurium cell expressing an E. cecorum glycan. Alternatively, the heterologous genes may be directly integrated into the host cell genome.
[0057] In at least one example, the heterologous expression of the E. cecorum glycosynthetic genes in the host bacterium produces an E. cecorum glycan having a structure that differs from the corresponding glycan naturally produced by the / ■ / cecorum.
[0058] For example, when the heterologous glycan comprises the E. cecorum CPS, the CPS produced by the host bacterium may comprise a galacturonic acid (GalA) residue that is O-acetylated 14WSLEGAL\088094\00003\44113916v7at the second carbon or the third carbon, including in an approximate 1 : 1 ratio of 2-O-acetylated GalA residues to 3-O-acetylated GalA residues. In some embodiments, the ratio is between about 0.7: 1.0 to about 1.0:0.7, preferably between about 0.8: 1.0 to about 1.0:0.8, or more preferably between about 0.9: 1.0 to about 1.0:0.9. The CPS produced by the host bacterium may differ from a naturally produced E. cecorum CPS in which GalA residues are present as unacetylated GalA, 2-O-acetylated GalA, and 3-O-acetylated GalA in an approximate 1:1:3 ratio of repeating units.
[0059] In another example, when the heterologous glycan comprises an E. cecorum RPS, the RPS produced by the host bacterium may differ from a naturally produced E. cecorum RGP by lacking a glucose side chain.IV. METHODS OF ADMINISTRATION
[0060] Provided are methods of inducing or eliciting an immune response in an animal by administering to the animal a composition or formulation described herein. In embodiments of such methods, the composition is administered to the subject in an amount capable of inducing or eliciting a protective immune response against the modified S. Typhimurium of the composition.
[0061] An amount of the composition capable of inducing or eliciting a protective immune response in a subject can be described as an pharmaceutically effective amount or immunologically effective amount, both considered to be an “ effective amount within the context of this disclosure, and may be administered as one dose or as two or more doses.
[0062] Generally, an immunogenically effective amount refers to an amount that induces an immune response, e.g., antibodies (humoral) against the immunogenic E. cecorum glycans when administered to a subject. The compositions may also induce cellular (non-humoral) immune responses. Effective amounts and schedules for administration may be determined empirically.
[0063] In some embodiments, the animal is administered more than one dose of the composition over a period of time. For example, the animal may be administered an initial effective dose (or effective amount) of the composition on day 1, followed by one or more effective doses of the composition at appropriate time intervals. In some instances, the subsequent doses are booster doses having the same dosage as the first effective dose. In some instances, the subsequent doses are booster doses having a lower or a higher dosage in reference to the first effective dose.15WSLEGAL\088094\00003\44113916v7
[0064] Dosage ranges for administration of the compositions described in the present disclosure are those large enough to produce the desired effect — i.e. eliciting a protective immune response against the immunogenic carbohydrate compound of the composition in the animal; particularly, against the microorganism or cell that expresses the immunogenic carbohydrate compound. The dosage should not be so large as to cause substantial adverse side effects, such as unwanted crossreactions, anaphylactic reactions, and the like. Generally, the dosage may vary with the age, condition, sex, medical status, route of administration, or whether other drugs are included in the regimen. The dosage can be adjusted by a medical professional in the event of any contraindications. Dosages can vary, and the agent can be administered in one or more dose administrations daily, for one or several days, including a prime and boost paradigm.
[0065] The compositions and formulations described herein can be administered via any of several routes of administration, including, but not limited to, orally, parenterally, intravenously, intramuscularly, subcutaneously, transdermally, by nebulization / inhalation, or by installation via bronchoscopy. Administration can be by oral inhalation, nasal inhalation, or intranasal mucosal administration. Administration by inhalant can be through the nose or mouth via delivery by spraying or droplet mechanism, for example, in the form of an aerosol. In some embodiments, administration is intramuscular or subcutaneous. In another embodiment the vaccine may be formulated for in ovo administration, for addition to animal feed, feed additives or water.
[0066] As used throughout, “anima includes domesticated animals, such as cats, dogs, etc., livestock (for example, poultry, cattle, horses, pigs, sheep, goats, etc.) and laboratory animals (for example, ferret, chinchilla, mouse, rabbit, rat, gerbil, guinea pig, etc.). Thus, veterinary uses and medical uses and formulations for non-humans are contemplated herein. The term does not denote a particular age or sex. Thus, adult and newborn animals, whether male or female, are intended to be covered.
[0067] The methods according to the embodiments of the present disclosure are useful for both prophylactic and therapeutic purposes. Methods of treating or preventing an infection in a subject, which include administering to a subject with an infection or susceptible to an infection an effective dose of compositions or formulations described herein are also included among the embodiments of the present disclosure. In some embodiments, a composition or formulation as described herein can16WSLEGAL\088094\00003\44113916v7be used alone or in combination with one or more therapeutic agents such as, for example, antiviral compounds for the treatment of a viral infection or disease.
[0068] For prophylactic use, an effective amount of a composition or formulation described herein can be administered to a subject prior to onset of an infection (for example, before obvious signs of infection) or during early onset (for example, upon initial signs and symptoms of infection). Prophylactic administration can be used, for example, in the preventative treatment of subjects identified as having a predisposition to an infection. Therapeutic treatment involves administering to a subject a therapeutically effective amount of a composition described in the present disclosure after diagnosis or development of infection.V. ANTIBODIES AND DIAGNOSTIC ASSAYS
[0069] As used herein, the term “antibody” refers to an immunoglobulin molecule, or an antigenbinding portion thereof, that specifically binds to an antigen or epitope. The term includes, without limitation, monoclonal antibodies, polyclonal antibodies, recombinant antibodies, engineered antibodies, chimeric antibodies, humanized antibodies, single-chain antibodies, antibody fragments, antigen-binding fragments. The term further includes avian antibodies, including chicken immunoglobulin Y (IgY).
[0070] An antibody of this invention “which binds” an antigen of interest is one that binds the antigen with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent in targeting a protein or a cell or tissue expressing the antigen, and does not significantly cross-react with other proteins. In such embodiments, the extent of binding of the antibody to a “non-targef ’ protein will be less than about 10% of the binding of the antibody to its particular target as determined by fluorescence activated cell sorting (FACS) analysis or radioimmunoprecipitation (RIA) or ELISA. With regard to the binding of an antibody to a target molecule, the term “specific binding” or “specifically binds to” or is “specific for” a particular polypeptide or an epitope on a particular polypeptide target means binding that is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule. For example, specific binding can be determined by competition with a control molecule that is similar to the target, for example, an excess of non-labeled target. In this case, specific binding is indicated if the binding of the labeled target to a probe is competitively inhibited by excess 17WSLEGAL\088094\00003\44113916v7unlabeled target. The term “specific binding” or “specifically binds to” or is “specific for” a particular polypeptide or an epitope on a particular polypeptide target as used herein can be exhibited, for example, by a molecule having a Kd for the target of at least about 104M, alternatively at least about 105M, alternatively at least about 106M, alternatively at least about 107M, alternatively at least about 10sM, alternatively at least about 109M, alternatively at least about 1010M, alternatively at least about 1011M, alternatively at least about 1012M, or greater. In one embodiment, the term “specific binding” refers to binding where a molecule binds to a particular glycan or epitope on a particular glycan without substantially binding to any other glycan or glycan epitope. These amounts are not meant to be limiting, and increments between the recited values are specifically envisioned as part of the disclosure.
[0071] Antibodies that bind specifically to an E. cecorum surface glycan may recognize an epitope of an E. cecorum capsular polysaccharide (CPS), rhamnopolysaccharide (RPS), rhamnose-glucose polysaccharide (RGP), or a teichoic acid-associated glycan.
[0072] In some examples, the antibody is generated by immunizing an animal with a vaccine composition comprising an engineered bacterium that expresses an E. cecorum surface glycan on its cell surface, as described above.
[0073] A serum or antibody-containing preparation comprising an antibody that binds specifically to an E. cecorum surface glycan may then be administered to an animal in an effective amount. For example, it can be administered in an effective amount to treat or prevent enterococcal spondylitis, vertebral osteoarthritis, kinky back, an E. cecorum infection, or a disease caused by a microbe expressing a glycan epitope that is immunologically cross-reactive with an E. cecorum surface glycan.
[0074] The antibody may also be used in an assay to detect A. cecorum in a sample obtained from an animal or an environment. The assay may comprise, for example, an enzyme-linked immunosorbent assay, immunoblot assay, lateral flow assay, agglutination assay, immunofluorescence assay, flow cytometry assay, or other immunoassay in which binding of the antibody to the sample indicates the presence of E. cecorum or an E. cecorwm-associated glycan.
[0075] In some examples, an antibody or serum comprising the antibody - that binds specifically to an E. cecorum surface glycan - is used in an opsonophagocytosis assay to evaluate binding to E. cecorum cells, killing of E. cecorum cells, or both. The assay may comprise contacting E. cecorum 18WSLEGAL\088094\00003\44113916v7cells with the antibody or serum and phagocytic cells, incubating the mixture under conditions that permit opsonization and phagocytosis, and measuring bacterial survival or percent bacterial killing relative to a control.VI. EXAMPLES
[0076] The following examples are offered to illustrate, but not to limit the claimed disclosure. Methods and materials are provided below.Example 1
[0077] Three field isolates of E. cecorum cultured from the free thoracic vertebrae of chickens experiencing kinky back were sequenced. These isolates are designated as Rl-3. CPS core and extension were then identified, as well as the RGP locus in these genomes by alignment with the relevant regions from E. cecorum SA3 (Borst et al., 2015, see Figure 1 for genomic locations).
[0078] The regions from E. cecorum R1 were then aligned to all E. cecorum genomes available in the National Center for Biotechnology Information (NCBI) database. From these, we determined that 167 were likely from pathogenic isolates from chickens based on metadata retrieved from NCBI or the publications related to the sequences (Borst et al., 2015; Combar et al., 2024; Dolka et al., 2015; Huang et al., 2024; Laurentie et al., 2023; Rhoads et al., 2024) suggesting samples originated from bone or tissue samples of chickens experiencing symptoms of kinky back.
[0079] The conservation of the loci was highest among European isolates and most divergent in Australian isolates.
[0080] Overall, the CPS core locus was found in 87% of pathogenic isolates and its extension was found in 73% of pathogenic isolates. Furthermore, the RGP biosynthetic locus was found in 75% of pathogenic isolates (Table 1).Table 1 : Proportion of Sequenced Pathogenic E. cecorum Genomes Possessing CPS and RGP LociOverall Belgium France Poland USA Australia (10)(167) (1) (100) (6) (50) CPS core (LEFALG 06975 to 87% 50% 100% 96% 83% 78%19WSLEGAL\088094\00003\44113916v7LEFALG 06890)CPS extension(LEFALG 06775 to 73% 40% 100% 81% 83% 62% LEFALG 06700)RGP locus (LEFALG 0155575% 40% 100% 81% 67% 70% to LEFALG 01620)
[0081] Particularly, Table 1 shows the percent of sequences from E. cecorum isolated from bone or tissue samples from chickens showing clinical signs of disease that possess the indicated capsular polysaccharide (CPS) and rhamnose-glucose polysaccharide (RGP) loci. The number of sequences in each sample set is indicated in parentheses.
[0082] To assess the immunogenic potential of the highly conserved surface glycans, E. cecorum R1 was grown in brain-heart infusion (BHI) broth statically at 37 °C under aerobic conditions to an ODeoo of approximately 0.9. Cultures were washed with PBS and inactivated with 2% formalin, then washed again to remove all traces of formalin.
[0083] Complete cell inactivation was confirmed by testing an aliquot of cells for growth on BHI agar before and after formalin treatment. Inactivated cells were adjusted to ODeoo=l, pelleted, and resuspended in half the volume of PBS to create a 2X concentrated cell suspension.
[0084] The suspension was combined with Montanide 78 adjuvant in a 70:30 ratio and emulsified by passing the suspension through a double-hub injection needle 0.9 G20 twenty times. Healthy day-of-hatch male Ross x Ross chicks, vaccinated with a commercially approved coccidia vaccine at the normal recommended dosage were given two 0.15 ml doses at different injection sites per injection day via the intramuscular route in the pectoralis major muscle using 1 ml syringes in combination with 22 gauge or smaller needles on Days 7 and 21.
[0085] Animal care practices conformed to the Guide for the Care and Use of Agricultural Animals in Agricultural Research and Teaching (FASS, 2020). All birds were euthanized by methods approved by the American Veterinary Medical Association (AVMA) on Day 35 and blood was collected and clotted overnight. The sera supernatant was then used for testing immunogenicity.20WSLEGAL\088094\00003\44113916v7
[0086] Whole cell lysates of E. cecorum strains Rl-3 were prepared for SDS-PAGE visualization by adaptation of methods previously used for Gram positive organisms (Garber et al., 2025; Wenzel et al., 2020) and others for Enterococci (Teng et al., 2009).
[0087] Cells were grown overnight, washed with PBS and adjusted to ODeoo=2.0, then concentrated 10X. This solution was then treated lysozyme and nucleases and then Laemmli buffer (Laemmli, 1970) was added and samples were boiled to ensure complete cell lysis. Proteinase K (ThermoScientific) was added for protein-free samples.
[0088] Following this treatment, the tubes were boiled again for 20 minutes to inactivate the proteinase K. Samples were run on 12.5% / 5% SDS-PAGE gels at 200 V for 45 minutes. Gels were either Coomassie stained for protein visualization (Figure 2a) or silver stained for glycan visualization (Figure 2b) using established lab protocols (Garber et al., 2025).
[0089] The gel used for the immunoblot (Figure 2c) was transferred to methanol-activated PVDF in a wet transfer system using a modified transfer buffer (Misevic, 1989), at 75V for 45 minutes. Membranes were then probed with antisera based on our established protocol (Nothaft et al., 2010) using 1:100 antisera from vaccinated chickens as the primary antibody and 1:2500 alkaline phosphatase-conjugated (AP)-anti-chicken IgY secondary, followed by development with NBT / BCIP substrate according to manufacturer’s instructions.
[0090] Through this experiment, it was demonstrated that following intermuscular injection of inactivated A. cecorum Rl, chickens mount an immune response to carbohydrates and that the derived antibodies are cross-reactive against multiple Ec isolates as well as related Gram positive pathogens possessing RGP epitopes, including Streptococcus mutans (Figure 2c).Example 2
[0091] For heterologous expression of E. cecorum glycans, a non-pathogenic S. Typhimurium strain lacking all native glycosyltransferases (ST ArfbVUN, AwbaP) was produced, to minimize the risk of interference with the production of the heterologous glycan.
[0092] To clone the E. cecorum glycosynthetic genes, primers (Table 2) were designed based on the sequences of the CPS locus and RGP locus previously-identified in SA3 (Borst et al., 2015) to amplify genes predicted to be needed for assembling the polysaccharides. Restriction sites were added 21WSLEGAL\088094\00003\44113916v7to the primers for insertion into cloning vectors (Table 2). Due to the large size of the loci, and distant localization of some genes, the loci were each cloned in portions as indicated in Table 2.Table 2: Oligonucleotides for Cloning the E. cecorum Glycan Loci and Vectors for Heterologous ExpressionSize Primer Sequence and Annealing Vector and Target(bp) Restriction Site Temp. (°C) Restriction Sites GCTTAAGATCTTTATACTGA F ATAGGCATATCTAAGTTAG BglllCPS extension part 1G [SEQ ID NO: 1] pWSK29 (LEFALG 06775- 6734 55ATATCTCGAGCCTGAATTCT (BamHI / XhoI) LEFALG 06750)R ATTTATTTGATGCATTTG Xhol[SEQ ID NO: 2]ATATGGATCCAGAATTGAG F BamHICPS extension part 2 GAGCTACC [SEQ ID NO: 3]pBBRlMCS-2 (LEFALG 06755- 8298 ATATCTCGAGTATTTCAAA 50(BamHI / XhoI) LEFALG 06720) R ATTTACAGCTACC [SEQ ID XholNO: 4]ATATGGATCCGAGGTAGTT F TTTTTGAAAGTATTAAGAG BamHICPS extension part 3[SEQ ID NO: 5] pACYC184 (LEFALG 06715- 3800 53ATATGTCGACAATGATAAA (BamHI / Sall) LEFALG 06705)R ATTCCACTCGTGTAAATTC Sall[SEQ ID NO: 6]ATATGGATCCCTAAACGAA F TGAAAGCACAATTATTACA BamHIRGP epaA ETC [SEQ ID NO: 7] pACYC1841263 55(LEFALG 06035) ATATCTCGAGGTTCTCAAA (BamHI / Sall*)R CAATCAAGACTTACCTAAC Xhol[SEQ ID NO: 8]ATATCTCGAGATGACAGAT RGP epal pACYC1841080 F ATACTATGTTATCCTTTATA Xhol 55(LEFALG 01820) (BamHI / Sall*)C [SEQ ID NO: 9]22WSLEGAL\088094\00003\44113916v7ATATGTCGACGCTATCAATR AATATTGGAAAAAGTATCA SallTTAAATC [SEQ ID NO: 10]ATATGGATCCTGAAAGAGA RGP locus epaB-D F AGAATAGGAAG [SEQ ID BamHIpBBRlMCS-2 (LEFALG 01555- 2368 NO.: 11] 50(BamHI / Xbal) LEFALG 01565) GTCACAAGTTTCTAGATTTTR XbalG [SEQ ID NO: 12]ATATGGATCCTTTTAGTTAT F AGGACAGAAAG [SEQ ID BamHIRGP locus epaL-PNO: 13] pWSK29 (LEFALG 01595- 10512 50ATATCTCGAGTTGGCATAT (BamHI / XhoI) LEFALG 01620)R AAAATTATTTAAGC [SEQ ID XholNO: 14]*epaA and epal were ligated into pACYC184 in a single 3 -part ligation; F=forward primer, R=reverse primer, bp=base pairs.
[0093] Particularly, Table 2 shows oligonucleotides for cloning E. cecorum R1 capsular polysaccharide (CPS) and rhamnose glucose polysaccharide (RGP) loci, and vectors for heterologous expression. Gene names are indicated and restriction sites used in constructs are underlined in the primer sequence.
[0094] PCRs were done using Q5® High-Fidelity DNA Polymerase (New England Biolabs) according to manufacturer’s instructions with 1 pl of genomic DNA extracted from E. cecorum R1 (using the Qiagen QIAamp DNA Mini Kit with the protocol for Gram Positive organisms) as template material. Cycling conditions consisted of 30 seconds initial denaturation at 98 °C; which was followed by 30 cycles of denaturation at 98 °C for 10 seconds, annealing at the temperature indicated in Table 2 for 10 seconds, and extension at 72 °C for approximately 40 seconds per kB; and a final extension at 72 °C for 2 minutes. Plasmids and PCR products were purified using GeneJET kits (ThermoSci entific) according to manufacturer’s instructions, digested with FastDigest enzymes (ThermoSci entific) at 37 °C for 1 h, and ligated overnight at 16 °C using T4 DNA ligase (New England Biolabs) according to manufacturer’s instructions.23WSLEGAL\088094\00003\44113916v7
[0095] Ligations were initially transformed by standard methods into CaCh-competent Escherichia coli DH5a for plasmid maintenance, and then purified plasmid was electroporated into ST ArfbVUN, AwbaP. The strain with plasmids containing the CPS genes was designated as ST Ec-CPS and the strain with plasmids containing the RGP genes was designated as ST Ec-RGP.
[0096] Analysis of protein-free extracts by SDS-PAGE and silver staining as described for Example 1 detected a ladder-like structure that was only present in the S. Typhimurium (ST) that carried either the Ec-CPS genes (Figure 3a) or Ec-RGP genes (Figure 3c). To confirm that the heterologous glycans were similar to those in E. cecorum, inactivated cells were prepared as in Example 1 and combined 1:1 with Freund’s complete adjuvant (FC A) for Day 7 injections and Freund’s incomplete adjuvant (FIA) for Day 21 injections, administered as described in Example 1. Sera from chickens vaccinated with inactive S. Typhimurium (ST) Ec-CPS (Figure 3b) or ST Ec-RGP (Figure 3d) showed cross-reactivity against all E. cecorum isolates in our collection.Example 3
[0097] For structural characterization of the glycans in E. cecorum Rl, cells were grown in 12 L of brain-heart infusion (BHI) broth statically at 37 °C under aerobic conditions to an ODeoo of approximately 0.9. Cultures were harvested by centrifugation and washed with PBS.
[0098] Polysaccharides were isolated by phenol extraction and acetic acid precipitation, as well as treatment with nucleases, lysozyme, and proteinase K. Extracted polysaccharides were further purified by anion-exchange chromatography.
[0099] NMR experiments were carried out on a Bruker AVANCE III 600 MHz (1H) spectrometer with 5 mm Z-gradient probe with acetone internal reference (2.225 ppm for 1H and 31.45 ppm for 13C) using standard pulse sequences cosygpprqf (gCOSY), mlevphpr (TOCSY, mixing time 120 ms), roesyphpr (ROESY, mixing time 500 ms), hsqcedetgp (HSQC), hsqcetgpml (HSQC-TOCSY, 80 ms TOCSY delay) and hmbcgplpndqf (HMBC, 100 ms long range transfer delay).
[0100] Resolution was kept <3 Hz / pt in F2 in proton-proton correlations and <5 Hz / pt in F2 of H-C correlations. The spectra were processed and analyzed using the Bruker Topspin 2.1 program. Monosaccharides were identified by COSY, TOCSY and NOESY cross peak patterns and 13C NMR chemical shifts.24WSLEGAL\088094\00003\44113916v7
[0101] Amino group location was concluded from high field signal position of aminated carbons (CH at 45-60 ppm). Connections between monosaccharides were determined from transglycosidic NOE and HMBC correlations.
[0102] The NMR studies confirmed that E. cecorum R1 produces RGP (Figure 4a, Table 3), consisting of a repeating unit with two a-l,2-linked rhamnoses (Rha) and one a-1,3- Rha along the backbone with one P-l,2-linked glucose (Glc) added to the a-l,3-linked rhamnose (Figure 2c):A C B[-3-a-L-Rha-2-a-L-Rha-a-2-L-Rha-]|2P-GlcDTable 3: NMR Data for A. cecorum R1 RGP (600 MHz, 25 °C, bppm) Sugar 11.( 1 11.( 2 H / C3 H / C4 H / C 5 11 / ( 6a-Rha A H 5.30 4.26 3.97 3.66 3.78 1.28C 102.2 80.4 77.3 73.4 70.5 17.9a-Rha B H 5.20 4.07 3.90 3.52 3.80 1.35C 102.0 79.0 71.2 73.3 70.5 18.0a-Rha C H 5.11 4.12 3.91 3.49 3.71 1.29C 102.0 79.2 71.2 73.3 70.6 18.0p-Glc D H 4.60 3.34 3.50 3.43 3.43 3.74; 3.88C 105.5 74.5 76.8 70.6 77.0 61.5
[0103] The RGP composition is consistent with the functions predicted based on homology to the reference E. cecorum S A3 genome and conserved domain searches of the gene products from the RGP locus.
[0104] E. cecorum R1 also expresses a capsular polysaccharide consisting of a -4-a-L- N-acetylfucosamine (FucNAc)-4-a-D- galacturonic acid (GalA)-3-a-D- N-acetylquinovosamine25WSLEGAL\088094\00003\44113916v7(QuiNAc)-3-a-L-Rha- repeat (Figure 4d, f; Table 4) that is consistent with the predicted enzymatic functions of the CPS extension (Figure 1):B A C D-4-a-L-FucNAc-4-a-D-GalA2OAc / 3OAc-3-a-D-QuiNAc-3-a-L-Rha-A - no Ac (not present in native PS); A' - 30Ac; A" - 20AcA: A': A" - 0:4:1NOE: A1:C2,C3,C4; B1:A4; C1:D2,D3,D4; D1:B3,B4.Table 4: NMR data for A. cecorum R1 CPS and O-deacylated E. cecorum R1 CPSUnit 1 2 3 4 5 6 a-GalA A dPS H 5.37 3.97 4.00 4.37 4.37C 101.7 69.7 71.0 77.5 71.8 173.2 a-GalA3OAc A' PS 5.43 4.20 5.26 4.52 4.60101.6 68.1 73.3 74.9 71.4 173.2 a-GalA2OAc A" PS 5.51 5.10 4.26 4.48 4.5298.7 71.7 68.2 77.4 71.4a-FucNAc B dPS H 5.30 4.11 3.99 3.83 4.01 1.18C 99.1 51.0 67.9 81.7 68.5 16.8 a-FucNAc B' PS 5.08 4.14 3.99 3.85 3.89 1.1898.5 50.7 67.3 81.4 68.6 16.8 a-FucNAc B" PS 5.32 4.12 4.00 3.85 3.95 1.1899.3 50.8 67.8 81.4 68.7 16.8 a-QuiNAc C PS, dPS H 4.99 4.09 3.89 3.47 4.11 1.27C 95.5 53.4 80.6 77.1 68.9 17.7 a-Rha D PS, dPS H 4.85 4.19 3.87 3.53 4.14 1.27C 102.8 68.0 76.7 71.4 70.4 17.726WSLEGAL\088094\00003\44113916v7
[0105] Also identified were a teichoic acid polymer made from glycerol phosphate with - -6-a-Gal-2-a-Glc-l-Gro based lipid anchor (LTA, Figure 5, Table 5):1 2 3Y: -P-OCH2CHCH2OHIO-P-1 2 3W: HOCH2CHCH2OHIO-P-1 2 3T: -P-OCH2CHOHCH2O-P-1 2 3Z: -P-OCH2CHOHCH2OH-P-6-a-Gal-2-a-Glc-l-GroB A XNOE: A1:X1; B1:A2.Table 5:JH and13C NMR data (8, ppm, D2O, 35°C, 600 MHz) for the O-deacylated LTA from E.cecorum R1Sugar 1 2 3 4 5 6 a-Glc A H 5.16 3.70 3.83 3.49 3.70 3.77; 3.87C 97.1 76.7 72.7 70.7 73.0 61.827WSLEGAL\088094\00003\44113916v7a-Gal B H 5.13 3.85 3.95 4.07 4.32 4.05; 4.05C 97.4 69.3 70.2 70.0 70.9 65.7 GroX H 3.53; 3.83 3.96 3.61; 3.68C 70.1 71.8 63.3Gro T H 3.97; 4.02 4.08 3.97; 4.02C 67.5 70.3 67.5GroW H 3.76; 3.76 4.26 3.76; 3.76C 62.3 78.6 62.3Gro Y H 4.08; 4.08 4.43 3.77; 3.81C 65.9 77.2 62.0Gro Z H 3.93; 3.99 3.92 3.62; 3.69C 67.9 71.8 63.3
[0106] In Table 5, assignment of the spectra allowed identification of the following components (atom numbering starts from glycosylation of phosphorylation location, P = phosphate). Z and W represent "non-reducing" (left) end of the polyglycerophosphate chain. Y and T are in the middle of the chain, T is the major component, the amount of Y is much less (ratio unable to be determined). Current data does not indicate the sequence of T and Y, or demonstrate that they are in the same or different chains. Assignment of the glycerol signals is based on the HSQC, HMBC and HSQC-TOCSY spectra (Figure 5b).
[0107] For verification of the heterologously-expressed structures, pellets of ST Ec-CPS and ST Ec-RGP were prepared similarly as for E. cecorum R1 in Example 2, with the modification of initial growth being done in six 1 L shaking cultures of 2xYT broth with appropriate antibiotics at 37 °C and 220 rpm.
[0108] NMR studies as described above confirmed that the heterologously expressed Ec-CPS structure is the same as the CPS that is naturally produced in E. cecorum Rl, with differences in acetylation of the galacturonic acid (GalA) residue (Figure 4e, Table 6).28WSLEGAL\088094\00003\44113916v7B A C D -4-a-L-FucNAc-4-a-D-GalA2OAc / 3OAc-3-a-D-QuiNAc-3-a-L-Rha- A' - 30 AcA" - 20AcA': A" ~ 1:1Table 6: NMR data for Heterologously-expressed E. cecorum-CPS (600 MHz, 30 °C).Unit 1 2 3 4 5 6 a-GalA3OAc5.43 4.17 5.21 4.47 4.39A’ HC 101.2 67.8 73.7 74.6 72.0 a-GalA2OAc5.48 5.12 4.22 4.46 4.33A" HC 98.5 71.6 68.7 76.5 72.0 a-FucNAc B’ H 5.08 4.12 4.02 3.83 3.98 1.17C 98.0 50.8 67.5 81.5 68.4 16.7 a-FucNAc B" H 5.37 4.12 4.02 3.83 4.00 1.18C 98.4 50.8 67.5 81.5 68.4 16.7 a-QuiNAc C H 5.00 4.12 3.94 3.50 4.09 1.27C 95.1 53.4 80.3 76.9 68.9 17.7 a-QuiNAc C" H 4.98 4.07 3.89 3.37 4.11 1.27C 95.0 53.4 79.8 77.3 68.9 17.7 a-Rha D’ H 4.85 4.20 3.87 3.52 4.10 1.27C 102.8 67.8 76.3 71.3 68.9 17.7 a-Rha D" H 4.84 4.19 3.85 3.52 4.10 1.27C 102.8 68.0 76.3 71.3 68.9 17.7OAc: 2.11 / 21.4; 2.18 / 21.5 ppm. NAc: 1.97 / 23.0; 1.99 / 23.0; 2.00 / 23.0 ppm.29WSLEGAL\088094\00003\44113916v7
[0109] The heterologous Ec-RGP structure has the same rhamnan backbone as the native structure, but lacks the glucose side chain (Figure 4c, Table 7):-2-a-Rha-3-a-Rha-2-a-Rha- A C Ba-Rha3OMe-3-a-Rha-2-a-Rha- =end of chainT C BTable 7: NMR data for Heterologously-Expressed E. cecorum RPS (D2O, 25 °C, 600 MHz).Unit H / C-l H / C-2 H / C-3 H / C-4 H / C-5 H / C-6a-Rha A H 5.17 4.09 3.96 3.51 3.84 1.32C 102.2 79.0 71.2 73.3 70.4 17.8a-Rha B H 5.12 4.11 3.92 3.50 3.72 1.29C 102.1 79.2 71.1 73.3 70.5 17.8a-Rha C H 4.98 4.16 3.85 3.57 3.77 1.28C 103.1 71.1 78.4 72.8 70.5 17.8a-Rha C H 4.98 4.16 3.84 3.57 3.77 1.28C 103.1 71.1 79.1 72.8 70.5 17.8a-Rha3OMe T H 5.09 4.33 3.56 3.49 3.86 1.31C 103.4 66.9 80.5 72.0 70.3 17.8
[0110] The heterologously expressed Ec-RPS comprises the same rhamnan backbone as the native Ec-RPS, but lacks the glucose side chain observed in the native Ec-RPS. The heterologously expressed Ec-RPS also retains the terminal 3-O-methyl-rhamnose residue present in the native Ec-RPS. The 3-O-methyl position was confirmed by HMBC data showing a correlation from the methyl group to C-3 of the terminal rhamnose residue.30WSLEGAL\088094\00003\44113916v7Example 4
[0111] Sera from chickens vaccinated with inactivated ST Ec-CPS or ST Ec-RPS as in Example 2 and Figure 6a were first screened by immunoblot for reactivity to whole cell lysates of E. cecorum and the heterologous strains as in Example 1. All sera reacted to their respective heterologous strain and E. cecorum (Figure 6b-c).
[0112] The strongest E. cecorum-reactive sera from the immunoblots were also screened by enzyme-linked immunosorbent assays (ELISA) using methods adapted from those previously used by our group (Harding et al., 2019; Nothaft et al., 2016). Briefly, ELISA plates were prepared used immobilized heated-inactivated E. cecorum, ST-EcCPS, ST-EcRPS, and ST ArfbVUN, AwbaP and probed with cross-adsorbed chicken sera diluted 1:50 in 2.5% skim milk in PBS-T and a secondary antibody solution consisting of alkaline phosphatase (AP)-anti-chicken IgY diluted 1:500 in PBS-T. Plates were developed with pNPP substrate following the instructions of the manufacturer.
[0113] Control wells containing no cells and control wells without sera were also included and the experiment was performed in triplicates.
[0114] Immunoreactivity in each serum sample was determined by measuring OD405 and subtracting the absorbances from the control wells without sera as background. Data were graphed and analyzed using GraphPad Prism. Significant binding was determined by comparing the signal from wells of each cell type to the control wells containing no cells using a Dunnet’s multiple comparisons test. Surface binding to multiple E. cecorum strains was observed (Figure 7a-b).
[0115] The two most reactive sera for each antigen, with the lowest background binding to ST, were pooled and used in an opsonophagocytosis assay (OP A). The study design was based on those previously used for other Gram-positive pathogens (Harding et al., 2019; Wenzel et al., 2020). Briefly, RPMI with glutamine cell culture medium was supplemented with 10 mM HEPES, 50 pM [3-mercaptoethanol, and 5% heat inactivated naive chicken serum.
[0116] Three replicate reactions in supplemented media containing ~5xl04CFU / ml E. cecorum Rl, -16% fresh heparinized chicken blood (collected from SPRG chickens that were not exposed to E. cecorum), and 20% serum from vaccinated chickens or naive controls were carried out at 37 °C in31WSLEGAL\088094\00003\44113916v75% CO2 for 3 h with occasional shaking. Aliquots of the starting cells (t=0 h timepoint) and each assay tube after 3 h were serially diluted in PBS and plated as 3 technical replicates on TH agar.
[0117] These replicates were incubated at 37 °C until countable CFU were evident. Following colony enumeration, bacterial killing was calculated using the following formula: (% bacteria killed = [(median # of cells in naive chicken serum reaction - # of cells recovered in the reaction of interest) / (median # of cells in naive chicken serum reaction)] x 100).
[0118] Data were plotted and statistically analyzed using GraphPad Prism to compare the percent killing in each vaccine sera to that in the naive sera using a Student’s t-test. Through this assay, we observed in vitro killing by phagocytic chicken blood cells with a median of over 90% of cells relative to naive serum (Figure 7c).Example 5
[0119] Passive protection and E. cecorum challenge studies were conducted using the same type of birds as described for serology studies and the same animal welfare practices described in Example 1. The study design (Figure 8a) was based on a previously-established model of kinky back (Borst et al., 2016). Birds were gavaged with a 1:1 mixture of A. cecorum SA3 (1.0 x 107cfu / bird, grown and provided by SPRG) and diluted sera from previous serology studies or a PBS control as indicated in Table 8 on Day 7. Additionally, some groups received a booster treatment on Day 14 (see Table 8).Table 8: Animal Study Design and Dosage.Day of GavageTreatment Number of TreatmentID Chicks Description7 140.1 mlT1 35 Challenge Control 0.1 ml PBS 0.1 ml PBS E. cecorum0.1 ml Sera 0.1 mlT2 35 ST Ec-CPS 0.1 ml Sera 1&31&3 (Figures 6-7) E. cecorum32WSLEGAL\088094\00003\44113916v70.1 ml Sera 0.1 mlT3 35 ST Ec-RPS 0.1 ml Sera 5&85&8 (Figures 6-7)) E. cecorum
[0120] On Day 21, 5 birds per treatment group were euthanized and spleens were homogenized in PBS per gram of tissue and used to inoculate Todd Hewitt broth, supplemented with 1% yeast extract (TH-Y) and 64 pg / ml amikacin, 8 pg / ml tetracycline, and 4 pg / ml erythromycin for an overnight enrichment growth at 37 °C in 5% CO2. Enrichment cultures were serially diluted and plated on Columbia Nalidixic Acid (CNA) agar. Colony forming units (CFU) were enumerated after 2-3 days when colonies appeared. The remaining birds were euthanized on Day 39, when some were exhibiting signs of kinky back deformation (Figure 8b).
[0121] Spleens were collected and processed as done for the Day 21 samples. Additionally, swabs of the free thoracic vertebrae (FTV) of all birds were collected and used to inoculated TH-Y with the selective antibiotics indicated above for enrichment prior to dilution and plating.
[0122] Data were plotted and statistically evaluated using GraphPad Prism. We observed a trend of reduced spleen colonization levels of E. cecorum in birds receiving sera from chickens previously vaccinated with ST Ec-CPS or ST Ec-RPS, with the greatest reduction in those receiving the ST Ec-CPS vaccine (Figure 9a). We also saw a trend towards reduced spinal colonization in birds receiving sera for passive immunization (Figure 9b).VII. INTERPRETATION
[0123] The forgoing description supplies specific details in order to provide a thorough understanding. Nevertheless, the skilled artisan would understand that the apparatuses, systems, and associated methods of using the apparatuses and systems can be implemented and used without employing these specific details. Indeed, the apparatuses, systems, and associated methods can be placed into practice by modifying the illustrated apparatus and associated methods and can be used in conjunction with any other apparatus and techniques conventionally used in the industry.
[0124] “About” is used to provide flexibility to a numerical range endpoint by providing that a given value may be “slightly above” or “slightly below” the endpoint without affecting the desired 33WSLEGAL\088094\00003\44113916v7result. For example, the term “about” would indicate a range surrounding that explicit value. If “X” were the value, “about X” would indicate a value from ±1% to ±10%, preferably a value from ±1% to ±5%, and more preferably, a value from ±1% to ±3%. Thus, “about X” is to teach and provide written description support for a claim limitation of, e.g., ±10%, ±5%, or ±3%.
[0125] The use herein of the terms “including,” “comprising,” or “having,” and variations thereof, is meant to encompass the elements listed thereafter and equivalents thereof as well as additional elements. Embodiments recited as “including,” “comprising,” or “having” certain elements are also contemplated as “consisting essentially of’ and “consisting of’ those certain elements. As used herein, “and / or” refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations where the phrase is interpreted in the alternative (“or”).
[0126] Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. For example, if a concentration range is stated as 1% to 50%, it is intended that values such as 2% to 40%, 10% to 30%, or 1% to 3%, etc., are expressly enumerated in this specification. These are only examples of what is specifically intended, and all possible combinations of numerical values between and including the lowest value and the highest value enumerated are to be considered to be expressly stated in this disclosure.
[0127] The corresponding structures, materials, acts, and equivalents of all means or steps plus function elements in the claims appended to this specification are intended to include any structure, material, or act for performing the function in combination with other claimed elements as specifically claimed.
[0128] References in the specification to "one embodiment", "an embodiment", etc., indicate that the embodiment described may include a particular aspect, feature, structure, or characteristic, but not every embodiment necessarily includes that aspect, feature, structure, or characteristic. Moreover, such phrases may, but do not necessarily, refer to the same embodiment referred to in other portions of the specification. Further, when a particular aspect, feature, structure, or characteristic is described in connection with an embodiment, it is within the knowledge of one skilled in the art to affect or connect such module, aspect, feature, structure, or characteristic with other embodiments, whether or 34WSLEGAL\088094\00003\44113916v7not explicitly described. In other words, any module, element or feature may be combined with any other element or feature in different embodiments, unless there is an obvious or inherent incompatibility, or it is specifically excluded.
[0129] It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for the use of exclusive terminology, such as "solely," "only," and the like, in connection with the recitation of claim elements or use of a "negative" limitation. The terms "preferably," "preferred," "prefer," "optionally," "may," and similar terms are used to indicate that an item, condition or step being referred to is an optional (not required) feature of the invention.
[0130] The singular forms "a," "an," and "the" include the plural reference unless the context clearly dictates otherwise. The term "and / or" means any one of the items, any combination of the items, or all of the items with which this term is associated. The phrase "one or more" is readily understood by one of skill in the art, particularly when read in context of its usage.
[0131] As will also be understood by one skilled in the art, all language such as "up to", "at least", "greater than", "less than", "more than", "or more", and the like, include the number recited and such terms refer to ranges that can be subsequently broken down into sub-ranges as discussed above. In the same manner, all ratios recited herein also include all sub-ratios falling within the broader ratio.VIII. REFERENCES
[0132] The following references are referred to herein and are indicative of the level of skill of one skilled in the art. Each reference is incorporated herein by reference, in their entirety, for all purposes.Borst, L. B., Suyemoto, M. M., Chen, L. R., & Barnes, H. J. (2019). Vaccination of breeder hens with a polyvalent killed vaccine for pathogenic Enterococcus cecorum does not protect offspring from enterococcal spondylitis. Avian Pathology, 48( 17-24. https: / / doi.org / 10.1080 / 03079457.2Q18.1536819Borst, L. B., Suyemoto, M. M., Sarsour, A. H., Harris, M. C., Martin, M. P, Strickland, J. D., Oviedo, E. O., & Barnes, H. J. (2016). Pathogenesis of Enterococcal Spondylitis Caused by 35WSLEGAL\088094\00003\44113916v7Enterococcus cecorum in Broiler Chickens. Veterinary Pathology, 54(1), 61-73. https: / / doi.org / 10.1177 / 0300985816658Q98Borst, L. B., Suyemoto, M. M., Scholl, E. H., Fuller, F. J., & Barnes, H. J. (2015). Comparative Genomic Analysis Identifies Divergent Genomic Features of Pathogenic Enterococcus cecorum Including a Type IC CRISPR-Cas System, a Capsule Locus, an c a-Like Locus, and Putative Host Tissue Binding Proteins. PLoS One, 10(4), e0121294. https: / / doi.org / 10.1371 / journal.pone.0121294Combar, D. O., Rubite, S., Scott, P. C., Campbell, B. E., & Van, T. T. H. (2024). Research Note: Comparison of Enterococcus cecorum genomes from broiler chickens with enterococcal spondylitis in Australian farms and strains from other countries. Poultry Science, 103(12), 104356. https: / / doi.Org / https: / / doi.org / 10.1016 / j.psj.2024.104356Dolka, B., Heidemann Olsen, R., Naundrup Thofner Ida, C., & Christensen Jens, P. (2015). Draft Genome Sequences of Five Clinical Enterococcus cecorum Strains Isolated from Different Poultry Species in Poland. Genome Announcements, 3(5), 10.1128 / genomea.01082-01015. https: / / doi.org / 10.1128 / genomea.01Q82-15Garber, J. M., Nothaft, H., Szymanski, C. M., & Wenzel, C. Q. (2025). Purification of Type IV and Type VI lipoteichoic acids from Gram-positive mucosal pathogens via a two-step hot water-phenol / triethylammonium acetate extraction method. In I. Brockhausen (Ed.), Methods in Molecular Biology: Dynamics of bacteria-mucus interactions. In press.Harding, C. M., Nasr, M. A., Scott, N. E., Goyette-Desjardins, G., Nothaft, H., Mayer, A. E., Chavez, S. M., Huynh, J. P, Kinsella, R. L., Szymanski, C. M., Stallings, C. L., Segura, M., & Feldman, M. F. (2019). A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host. Nat Commun, 10(1), 891. https: / / doi.org / 10.1038 / s41467-019-Q8869-9Huang, Y, Boyen, F., Antonissen, G., Vereecke, N., & Van Immerseel, F. (2024). The Genetic Landscape of Antimicrobial Resistance Genes in Enterococcus cecorum Broiler Isolates. Antibiotics, 13(5), 409. https: / / www.mdpi.eom / 2079-6382 / 13 / 5 / 409Jackson, C. R., Kariyawasam, S., Borst, L. B., Frye, J. G., Barrett, J. B., Hiott, L. M., & Woodley, T. A. (2015). Antimicrobial resistance, virulence determinants and genetic profiles of clinical 36WSLEGAL\088094\00003\44113916v7and nonclinical Enterococcus cecorum from poultry. Letters in Applied Microbiology , 60(2), 111-119. https: / / doi.org / 10.llll / lam.12374Jung, A., Chen, L. R., Suyemoto, M. M., Barnes, H. J., & Borst, L. B. (2018). A Review of Enterococcus cecorum Infection in Poultry. Avian Diseases, 62(3), 261-271. https: / / www.jstor.org / stable / 26537546Kay, E., Cuccui, J., & Wren, B. W. (2019). Recent advances in the production of recombinant glycoconjugate vaccines, npj Vaccines, 4(1), 16. https: / / doi.org / 10.1038 / s41541-019-011Q-zLaemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227(5259), 680-685. https: / / doi.org / 10.1038 / 22768Qa0Laurentie, J., Loux, V., Hennequet-Antier, C., Chambellon, E., Deschamps, J., Trotereau, A., Furlan, S., Darrigo, C., Kempf, E, Lao, J., Milhes, M., Roques, C., Quinquis, B., Vandecasteele, C., Boyer, R., Bouchez, O., Repoila, E, Le Guennec, J., Chiapello, H.,...Serror, P. (2023). Comparative Genome Analysis of Enterococcus cecorum Reveals Intercontinental Spread of a Lineage of Clinical Poultry Isolates. mSphere, 8(2), e0049522. https: / / doi.org / 10.1128 / msphere.0Q495-22Misevic, G. N. (1989). Immunoblotting and immunobinding of acidic polysaccharides separated by gel electrophoresis. In Methods in Enzymology (Vol. 179, pp. 95-104). Academic Press. https: / / doi.Org / https: / / doi.org / 10.1016 / 0076-6879(89)79117-5Nothaft, H., Davis, B., Lock, Y. Y, Perez-Munoz, M. E., Vinogradov, E., Walter, J., Coros, C., & Szymanski, C. M. (2016). Engineering the Campylobacter jejuni N-glycan to create an effective chicken vaccine. Scientific Reports, 6(1), 26511. https: / / doi.org / 10.1038 / srep26511Nothaft, H., Liu, X., McNally, D. J., & Szymanski, C. M. (2010). N-Linked Protein Glycosylation in a Bacterial System. In J. Li (Ed.), Functional Glycomics: Methods and Protocols (pp.227-243). Humana Press, https: / / doi.org / 10.1007 / 978-l-60761-454-8 16Rhoads, D. D., Pummill, J., & Alrubaye, A. A. K. (2024). Molecular Genomic Analyses of Enterococcus cecorum from Sepsis Outbreaks in Broilers. Microorganisms, 12(2). https: / / doi.org / 10.3390 / microorganismsl202025Q37WSLEGAL\088094\00003\44113916v7Rosenbaum, A., Rautenschlein, S., & Jung, A. (2025). Protective Effect of a Hyperimmune Serum Against Homologous Enterococcus cecorum Infection in Experimentally Challenged Meat-Type Chickens. Poultry, 4(1), 8. https: / / www.mdpi.eom / 2674-1164 / 4 / l / 8Teng, F., Singh, K. V., Bourgogne, A., Zeng, J., & Murray, B. E. (2009). Further Characterization of the epa Gene Cluster and Epa Polysaccharides of Enterococcus faecalis. Infection and Immunity, 77(9), 3759-3767. https: / / doi.Org / doi:10.1128 / iai.00149-09Wenzel, C. Q., Mills, D. C., Dobruchowska, J. M., Vlach, J., Nothaft, H., Nation, P, Azadi, P, Melville, S. B., Carlson, R. W., Feldman, M. E, & Szymanski, C. M. (2020). An atypical lipoteichoic acid from Clostridium perfringens elicits a broadly cross-reactive and protective immune response. J BiolChem, 295(28), 17. https: / / doi.org / 10.1074 / jbc.RA119.00997838WSLEGAL\088094\00003\44113916v7
Claims
CLAIMS:
1. A bacterium engineered to heterologously express an E. cecorum surface glycan comprising at least one of a capsular polysaccharide (CPS), a rhamnopolysaccharide (RPS), a lipotechoic acid (LTA), or a techoic acid-containing glycan.
2. The bacterium of claim 1, comprising a Gram-negative bacterium, such as a Salmonella enterica serovar Typhimurium or an Escherichia coli.
3. The bacterium of claim 2, which is live, attenuated S. Typhimurium or E. coli.
4. The bacterium of claim 2, which is inactivated or killed S. Typhimurium or E. coli.
5. The bacterium of any one of claims 1-4, comprising a non-pathogenic S. Typhimurium strain lacking all native glycosyltransferases.
6. The bacterium of any one of claims 1-5, wherein the surface glycan comprises a CPS, characterized by acetylation of a galacturonic acid (GalA) residue on either a second or a third carbon, in an approximate ratio of 1 : 1.
7. The bacterium of any one of claims 1-6, wherein the surface glycan comprises an RPS, characterized by the lack of a glucose side chain.
8. A vaccine composition comprising bacteria as claimed in any one of claims 1-7, and one or more of a physiologically acceptable diluent, excipient, adjuvant or carrier.
9. The vaccine composition of claim 8, wherein the composition is formulated for oral administration, in ovo administration or parenteral administration.
10. The vaccine composition of claim 8, wherein the composition is formulated to be sprayed or for addition to livestock feed, feed additive or water.
11. The vaccine composition of any one of claims 8-10, formulated for administration to poultry, for example, chickens.
12. An antibody that binds specifically to a E. cecorum surface glycan, such as an antibody isolated from an animal which has received a vaccine of any one of claims 8-11.39WSLEGAL\088094\00003\44113916v713. A method of treating or preventing a disease in a patient caused by a microbe which bears an E. cecorum surface glycan or a related glycan, by administrating to the patient a vaccine composition of any one of claims 8-11, or the antibody of claim 12.
14. The method of claim 13 which is a method of preventing kinky back in poultry, comprising the step of administering a vaccine composition of any one of claims 8-11 to the poultry 15. A method of diagnosing an infection caused by E. cecorum by using the antibody of claim 12, in an assay to recognize E. cecorum species in a sample.
16. A method of evaluating E. cecorum binding and killing by opsonophagocytosis, comprising the step of using the antibody of claim 12 in an opsonophagocytosis killing assay.40WSLEGAL\088094\00003\44113916v7
